|
Video: What is a Stock Split?
|
|
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of solid tumors and other diseases. Co.'s development pipeline includes: LSTA1, which is used in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma, in combination with a variety of anti-cancer regimens; HONEDRA®, which is designed for the treatment of critical limb ischemia and Buerger's disease; and LSTA201, which is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes. According to our LSTA split history records, Lisata Therapeutics has had 1 split. | |
|
Lisata Therapeutics (LSTA) has 1 split in our LSTA split history database. The split for LSTA took place on September 15, 2022. This was a 1 for 15 reverse split, meaning for each 15 shares of LSTA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Lisata Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the LSTA split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lisata Therapeutics shares, starting with a $10,000 purchase of LSTA, presented on a split-history-adjusted basis factoring in the complete LSTA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$106.95 |
|
End price/share: |
$3.12 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.08% |
|
Average Annual Total Return: |
-29.78% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$291.76 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
09/15/2022 | 1 for 15 |
|
|